Innate Pharma (IPHA) Fundamental Analysis: Revenue, Earnings & Valuation

3.28 / 10

Netural

Fundamental analysis scores 3.3/10, indicating subpar quality. Gross profit margin is high (100%) but carries negative weight, while inventory turnover is decent. Low current‑asset turnover and high cost‑of‑sales ratio weaken the profile, leading to a constrained financial outlook.

Analysis Checks(4/6)

Inventory turnover ratio

Value37.80

Score2/3

Weight26.32%

1M Return-0.56%

Gross profit margin (%)

Value100.00

Score2/3

Weight-91.96%

1M Return1.67%

Income tax / Total profit (%)

Value17.82

Score1/3

Weight-10.02%

1M Return0.21%

Current assets turnover ratio

Value0.06

Score1/3

Weight8.91%

1M Return-0.17%

Fixed assets turnover ratio

Value0.96

Score2/3

Weight-0.49%

1M Return0.01%

Cost of sales ratio (%)

Value73.08

Score2/3

Weight167.24%

1M Return-3.62%

Is IPHA fundamentally strong?

IPHA scores 3.28/10 on fundamentals and holds a Fair valuation at present. Backed by its 0.00% ROE, -546.11% net margin, -2.11 P/E ratio, -4.78 P/B ratio, and -2.23% earnings growth, these metrics solidify its Netural investment rating.